{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T07:06:37Z","timestamp":1781939197716,"version":"3.54.5"},"reference-count":88,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","translationalres.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Research"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.trsl.2021.12.006","type":"journal-article","created":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T02:36:21Z","timestamp":1640226981000},"page":"56-65","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"special_numbering":"C","title":["An mRNA vaccine to prevent genital herpes"],"prefix":"10.1016","volume":"242","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8230-3635","authenticated-orcid":false,"given":"Sita","family":"Awasthi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harvey M.","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trsl.2021.12.006_bib0001","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2471\/BLT.19.237149","article-title":"Herpes simplex virus: global infection prevalence and incidence estimates, 2016","volume":"98","author":"James","year":"2020","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.trsl.2021.12.006_bib0002","article-title":"Global estimates of prevalent and incident herpes simplex virus type 2 infections in 2012","volume":"10","author":"Looker","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.trsl.2021.12.006_bib0003","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1086\/315395","article-title":"Herpes simplex virus type 1 as a cause of genital herpes: impact on surveillance and prevention","volume":"181","author":"Lafferty","year":"2000","journal-title":"J Infect Dis"},{"key":"10.1016\/j.trsl.2021.12.006_bib0004","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12916-019-1285-x","article-title":"Characterizing the transitioning epidemiology of herpes simplex virus type 1 in the USA: model-based predictions","volume":"17","author":"Ayoub","year":"2019","journal-title":"BMC Med"},{"key":"10.1016\/j.trsl.2021.12.006_bib0005","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1136\/sextrans-2013-051453","article-title":"Herpes simplex virus type 1 genital herpes in young women: current trend in Northern Finland","volume":"90","author":"Tuokko","year":"2014","journal-title":"Sex Transm Infect"},{"key":"10.1016\/j.trsl.2021.12.006_bib0006","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1093\/cid\/ciy562","article-title":"The epidemiology of herpes simplex virus type 1 in Asia: systematic review, meta-analyses, and meta-regressions","volume":"68","author":"Khadr","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.trsl.2021.12.006_bib0007","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1136\/sti.2004.012039","article-title":"A systematic review of the epidemiology and interaction of herpes simplex virus types 1 and 2","volume":"81","author":"Looker","year":"2005","journal-title":"Sex Transm Infect"},{"key":"10.1016\/j.trsl.2021.12.006_bib0008","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1016\/S0140-6736(07)61908-4","article-title":"Genital herpes","volume":"370","author":"Gupta","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.trsl.2021.12.006_bib0009","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1001\/jama.2011.420","article-title":"Genital shedding of herpes simplex virus among symptomatic and asymptomatic persons with HSV-2 infection","volume":"305","author":"Tronstein","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.trsl.2021.12.006_bib0010","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/bmj.39409.673657.AE","article-title":"Viral meningitis","volume":"336","author":"Logan","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.trsl.2021.12.006_bib0011","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1055\/s-0032-1332802","article-title":"Maternal and neonatal herpes simplex virus infections","volume":"30","author":"Pinninti","year":"2013","journal-title":"Am J Perinatol"},{"key":"10.1016\/j.trsl.2021.12.006_bib0012","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/0002-9378(82)90686-X","article-title":"Recurrent genital herpes simplex virus infection in pregnancy: infant outcome and frequency of asymptomatic recurrences","volume":"143","author":"Vontver","year":"1982","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.trsl.2021.12.006_bib0013","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1056\/NEJM199105023241804","article-title":"Neonatal herpes simplex virus infection in relation to asymptomatic maternal infection at the time of labor","volume":"324","author":"Brown","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2021.12.006_bib0014","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1056\/NEJM198701293160503","article-title":"Low risk ofherpes simplex virus infections in neonates exposed to the virus at the time of vaginal delivery to mothers with recurrent genital herpes simplex virus infections","volume":"316","author":"Prober","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2021.12.006_bib0015","doi-asserted-by":"crossref","first-page":"e300","DOI":"10.1016\/S2214-109X(16)30362-X","article-title":"First estimates of the global and regional incidence of neonatal herpes infection","volume":"5","author":"Looker","year":"2017","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.trsl.2021.12.006_bib0016","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S1473-3099(19)30470-0","article-title":"Global and regional estimates of the contribution of herpes simplex virus type 2 infection to HIV incidence: a population attributable fraction analysis using published epidemiological data","volume":"20","author":"Looker","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.trsl.2021.12.006_bib0017","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1086\/338231","article-title":"Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis","volume":"185","author":"Wald","year":"2002","journal-title":"J Infect Dis"},{"key":"10.1016\/j.trsl.2021.12.006_bib0018","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/01.aids.0000198081.09337.a7","article-title":"Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies","volume":"20","author":"Freeman","year":"2006","journal-title":"AIDS"},{"key":"10.1016\/j.trsl.2021.12.006_bib0019","doi-asserted-by":"crossref","first-page":"231","DOI":"10.4161\/hv.4529","article-title":"Effectiveness and efficiency of imperfect therapeutic HSV-2 vaccines","volume":"3","author":"Schwartz","year":"2007","journal-title":"Human Vaccines"},{"key":"10.1016\/j.trsl.2021.12.006_bib0020","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1086\/429299","article-title":"Predicting the potential individual- and population-level effects of imperfect herpes simplex virus type 2 vaccines","volume":"191","author":"Schwartz","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1016\/j.trsl.2021.12.006_bib0021","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/OLQ.0b013e3181d3d023","article-title":"Population level impact of an imperfect prophylactic vaccine for herpes simplex virus-2","volume":"37","author":"Alsallaq","year":"2010","journal-title":"Sex Transm Dis"},{"issue":"suppl 1","key":"10.1016\/j.trsl.2021.12.006_bib0022","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1086\/425271","article-title":"Role of herd immunity in determining the effect of vaccines against sexually transmitted disease","volume":"191","author":"Garnett","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1016\/j.trsl.2021.12.006_bib0023","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1136\/sti.2002.003848","article-title":"The potential epidemiological impact of a genital herpes vaccine for women","volume":"80","author":"Garnett","year":"2004","journal-title":"Sex Transm Infect"},{"key":"10.1016\/j.trsl.2021.12.006_bib0024","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1001\/jama.282.4.331","article-title":"Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group.[see comment]","volume":"282","author":"Corey","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.trsl.2021.12.006_bib0025","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1056\/NEJMoa011915","article-title":"Glycoprotein-D-adjuvant vaccine to prevent genital herpes","volume":"347","author":"Stanberry","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2021.12.006_bib0026","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa1103151","article-title":"Efficacy results of a trial of a herpes simplex vaccine","volume":"366","author":"Belshe","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2021.12.006_bib0027","doi-asserted-by":"crossref","first-page":"889","DOI":"10.7326\/0003-4819-122-12-199506150-00001","article-title":"A recombinant glycoprotein vaccine for herpes simplex virus type 2: safety and immunogenicity [corrected][erratum appears in Ann Intern Med 1995 Sep 1;123(5):395]","volume":"122","author":"Langenberg","year":"1995","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.trsl.2021.12.006_bib0028","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1086\/315208","article-title":"Limited antibody-dependent cellular cytotoxicity antibody response induced by a herpes simplex virus type 2 subunit vaccine","volume":"181","author":"Kohl","year":"2000","journal-title":"J Infect Dis"},{"key":"10.1016\/j.trsl.2021.12.006_bib0029","doi-asserted-by":"crossref","first-page":"7046","DOI":"10.1128\/jvi.65.12.7046-7050.1991","article-title":"Herpes simplex virus type 1 Fc receptor protects infected cells from antibody-dependent cellular cytotoxicity","volume":"65","author":"Dubin","year":"1991","journal-title":"J Virol"},{"key":"10.1016\/j.trsl.2021.12.006_bib0030","doi-asserted-by":"crossref","first-page":"8421","DOI":"10.1128\/JVI.01130-14","article-title":"Blocking herpes simplex virus 2 glycoprotein E immune evasion as an approach to enhance efficacy of a trivalent subunit antigen vaccine for genital herpes","volume":"88","author":"Awasthi","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.trsl.2021.12.006_bib0031","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1093\/infdis\/jit651","article-title":"Correlate of immune protection against HSV-1 genital disease in vaccinated women","volume":"209","author":"Belshe","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.trsl.2021.12.006_bib0032","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1093\/infdis\/jiu177","article-title":"Better neutralization of herpes simplex virus type 1 (HSV-1) than HSV-2 by antibody from recipients of GlaxoSmithKline HSV-2 glycoprotein D2 subunit vaccine","volume":"210","author":"Awasthi","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.trsl.2021.12.006_bib0033","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1093\/infdis\/jiz225","article-title":"A randomized, double-blind, placebo-controlled, phase 1 study of a replication-defective herpes simplex virus 2 vaccine, HSV529, in adults with or without HSV infection","volume":"220","author":"Dropulic","year":"2019","journal-title":"J Infect Dis"},{"key":"10.1016\/j.trsl.2021.12.006_bib0034","doi-asserted-by":"crossref","first-page":"e06054","DOI":"10.7554\/eLife.06054","article-title":"Herpes simplex type 2 virus deleted in glycoprotein D protects against vaginal, skin and neural disease","volume":"4","author":"Petro","year":"2015","journal-title":"eLife"},{"key":"10.1016\/j.trsl.2021.12.006_bib0035","doi-asserted-by":"crossref","first-page":"e88529","DOI":"10.1172\/jci.insight.88529","article-title":"HSV-2 \u0394gD elicits Fc\u03b3R-effector antibodies that protect against clinical isolates","volume":"1","author":"Petro","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.trsl.2021.12.006_bib0036","doi-asserted-by":"crossref","first-page":"370","DOI":"10.4049\/jimmunol.129.1.370","article-title":"Protection of neonatal mice against herpes simplex virus infection: probable in vivo antibody-dependent cellular cytotoxicity","volume":"129","author":"Kohl","year":"1982","journal-title":"J Immunol"},{"issue":"suppl 11","key":"10.1016\/j.trsl.2021.12.006_bib0037","doi-asserted-by":"crossref","first-page":"S950","DOI":"10.1093\/clind\/13.Supplement_11.S950","article-title":"Role of antibody-dependent cellular cytotoxicity in neonatal infection with herpes simplex virus","volume":"13","author":"Kohl","year":"1991","journal-title":"Rev Infect Dis"},{"key":"10.1016\/j.trsl.2021.12.006_bib0038","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1001\/jama.283.6.746","article-title":"Immunologic strategies for herpes vaccination","volume":"283","author":"Friedman","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.trsl.2021.12.006_bib0039","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/309633a0","article-title":"Glycoprotein C of herpes simplex virus 1 acts as a receptor for the C3b complement component on infected cells","volume":"309","author":"Friedman","year":"1984","journal-title":"Nature"},{"key":"10.1016\/j.trsl.2021.12.006_bib0040","first-page":"103","article-title":"Immune evasion by herpes simplex virus type 1, strategies for virus survival","volume":"114","author":"Friedman","year":"2003","journal-title":"Trans Am Clin Climatol Assoc"},{"key":"10.1016\/j.trsl.2021.12.006_bib0041","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/infdis\/jit458","article-title":"Seroprevalence of herpes simplex virus types 1 and 2\u2014United States, 1999\u20132010","volume":"209","author":"Bradley","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.trsl.2021.12.006_bib0042","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1038\/mt.2008.200","article-title":"Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability","volume":"16","author":"Karik\u00f3","year":"2008","journal-title":"Mol Ther"},{"key":"10.1016\/j.trsl.2021.12.006_bib0043","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1089\/nat.2018.0726","article-title":"Current status of messenger RNA delivery systems","volume":"28","author":"Stanton","year":"2018","journal-title":"Nucleic Acid Ther"},{"key":"10.1016\/j.trsl.2021.12.006_bib0044","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2021.12.006_bib0045","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa2028436","article-title":"Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults","volume":"383","author":"Anderson","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2021.12.006_bib0046","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa2107456","article-title":"Safety, immunogenicity, and efficacy of the BNT162b2 COVID-19 vaccine in adolescents","volume":"385","author":"Frenck","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2021.12.006_bib0047","doi-asserted-by":"crossref","first-page":"eaaw7083","DOI":"10.1126\/sciimmunol.aaw7083","article-title":"Nucleoside-modified mRNA encoding HSV-2 glycoproteins C, D, and E prevents clinical and subclinical genital herpes","volume":"4","author":"Awasthi","year":"2019","journal-title":"Sci Immunol"},{"key":"10.1016\/j.trsl.2021.12.006_bib0048","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.virol.2017.10.013","article-title":"Increased surface expression of HIV-1 envelope is associated with improved antibody response in vaccinia prime\/protein boost immunization","volume":"514","author":"Hogan","year":"2018","journal-title":"Virology"},{"key":"10.1016\/j.trsl.2021.12.006_bib0049","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008795","article-title":"An HSV-2 nucleoside-modified mRNA genital herpes vaccine containing glycoproteins gC, gD, and gE protects mice against HSV-1 genital lesions and latent infection","volume":"16","author":"Egan","year":"2020","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.trsl.2021.12.006_bib0050","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.immuni.2020.07.019","article-title":"A single immunization with nucleoside-modified mRNA vaccines elicits strong cellular and humoral immune responses against SARS-CoV-2 in mice","volume":"53","author":"Laczk\u00f3","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.trsl.2021.12.006_bib0051","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/s41586-020-2814-7","article-title":"COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses","volume":"586","author":"Sahin","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.trsl.2021.12.006_bib0052","doi-asserted-by":"crossref","DOI":"10.1172\/JCI152310","article-title":"Trivalent nucleoside-modified mRNA vaccine yields durable memory B cell protection against genital herpes in preclinical models","volume":"131","author":"Awasthi","year":"2021","journal-title":"J Clin Invest"},{"issue":"4949 Pt 1","key":"10.1016\/j.trsl.2021.12.006_bib0053","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1126\/science.1690918","article-title":"Direct gene transfer into mouse muscle in vivo","volume":"247","author":"Wolff","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.trsl.2021.12.006_bib0054","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1126\/science.1546298","article-title":"Reversal of diabetes insipidus in Brattleboro rats: intrahypothalamic injection of vasopressin mRNA","volume":"255","author":"Jirikowski","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.trsl.2021.12.006_bib0055","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/978-1-4939-6481-9_6","article-title":"Nucleoside modified mRNA vaccines for infectious diseases","volume":"1499","author":"Pardi","year":"2017","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.trsl.2021.12.006_bib0056","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1586\/14760584.2015.973859","article-title":"mRNA transcript therapy","volume":"14","author":"Weissman","year":"2015","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.trsl.2021.12.006_bib0057","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jconrel.2015.08.007","article-title":"Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes","volume":"217","author":"Pardi","year":"2015","journal-title":"J Control Release"},{"key":"10.1016\/j.trsl.2021.12.006_bib0058","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nature21428","article-title":"Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination","volume":"543","author":"Pardi","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.trsl.2021.12.006_bib0059","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1089\/hum.2018.145","article-title":"Purification of mRNA encoding chimeric antigen receptor is critical for generation of a robust T-cell response","volume":"30","author":"Foster","year":"2019","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.trsl.2021.12.006_bib0060","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.cell.2017.02.017","article-title":"Modified mRNA vaccines protect against Zika virus infection","volume":"168","author":"Richner","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.trsl.2021.12.006_bib0061","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nri3803","article-title":"A brief history of T cell help to B cells","volume":"15","author":"Crotty","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.trsl.2021.12.006_bib0062","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.immuni.2014.10.004","article-title":"T follicular helper cell differentiation, function, and roles in disease","volume":"41","author":"Crotty","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.trsl.2021.12.006_bib0063","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/imr.12512","article-title":"Tfh cells and HIV bnAbs, an immunodominance model of the HIV neutralizing antibody generation problem","volume":"275","author":"Havenar-Daughton","year":"2017","journal-title":"Immunol Rev"},{"key":"10.1016\/j.trsl.2021.12.006_bib0064","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1084\/jem.20171450","article-title":"Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses","volume":"215","author":"Pardi","year":"2018","journal-title":"J Exp Med"},{"key":"10.1016\/j.trsl.2021.12.006_bib0065","doi-asserted-by":"crossref","first-page":"800","DOI":"10.3390\/v4050800","article-title":"Herpes virus fusion and entry: a story with many characters","volume":"4","author":"Eisenberg","year":"2012","journal-title":"Viruses"},{"key":"10.1016\/j.trsl.2021.12.006_bib0066","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1128\/JVI.06480-11","article-title":"Antibody-induced conformational changes in herpes simplex virus glycoprotein gD reveal new targets for virus neutralization","volume":"86","author":"Lazear","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.trsl.2021.12.006_bib0067","doi-asserted-by":"crossref","first-page":"4479","DOI":"10.1128\/jvi.63.11.4479-4488.1989","article-title":"A novel function of the herpes simplex virus type 1 Fc receptor: participation in bipolar bridging of antiviral immunoglobulin G","volume":"63","author":"Frank","year":"1989","journal-title":"J Virol"},{"key":"10.1016\/j.trsl.2021.12.006_bib0068","doi-asserted-by":"crossref","first-page":"10472","DOI":"10.1128\/JVI.00849-11","volume":"85","author":"Awasthi","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.trsl.2021.12.006_bib0069","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1128\/JVI.03163-13","article-title":"Protection provided by a herpes simplex virus 2 (HSV-2) glycoprotein C and D subunit antigen vaccine against genital HSV-2 infection in HSV-1-seropositive guinea pigs","volume":"88","author":"Awasthi","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.trsl.2021.12.006_bib0070","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1128\/JVI.02509-10","article-title":"Herpes simplex virus type 1 IgG Fc receptor blocks antibody-mediated complement activation and antibody-dependent cellular cytotoxicity in vivo","volume":"85","author":"Lubinski","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.trsl.2021.12.006_bib0071","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006141","article-title":"An HSV-2 trivalent vaccine is immunogenic in rhesus macaques and highly efficacious in guinea pigs","volume":"13","author":"Awasthi","year":"2017","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.trsl.2021.12.006_bib0072","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2019-001875","article-title":"The global and regional burden of genital ulcer disease due to herpes simplex virus: a natural history modelling study","volume":"5","author":"Looker","year":"2020","journal-title":"BMJ Glob Health"},{"key":"10.1016\/j.trsl.2021.12.006_bib0073","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/S1473-3099(17)30405-X","article-title":"Effect of HSV-2 infection on subsequent HIV acquisition: an updated systematic review and meta-analysis","volume":"17","author":"Looker","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.trsl.2021.12.006_bib0074","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1056\/NEJM199102143240704","article-title":"Predictors of morbidity and mortality in neonates with herpes simplex virus infections. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group","volume":"324","author":"Whitley","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2021.12.006_bib0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/CMR.17.1.1-13.2004","article-title":"Neonatal herpes simplex infection","volume":"17","author":"Kimberlin","year":"2004","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.trsl.2021.12.006_bib0076","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJMoa1003509","article-title":"Oral acyclovir suppression and neurodevelopment after neonatal herpes","volume":"365","author":"Kimberlin","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2021.12.006_bib0077","doi-asserted-by":"crossref","first-page":"eaau6039","DOI":"10.1126\/scitranslmed.aau6039","article-title":"Maternal immunization confers protection against neonatal herpes simplex mortality and behavioral morbidity","volume":"11","author":"Patel","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.trsl.2021.12.006_bib0078","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02163-19","article-title":"Trivalent glycoprotein subunit vaccine prevents neonatal herpes simplex virus mortality and morbidity","volume":"94","author":"Patel","year":"2020","journal-title":"J Virol"},{"key":"10.1016\/j.trsl.2021.12.006_bib0079","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1093\/infdis\/jiz521","article-title":"Murine model of maternal immunization demonstrates protective role for antibodies that mediate antibody-dependent cellular cytotoxicity in protecting neonates from herpes simplex virus type 1 and type 2","volume":"221","author":"Kao","year":"2019","journal-title":"J Infect Dis"},{"key":"10.1016\/j.trsl.2021.12.006_bib0080","doi-asserted-by":"crossref","first-page":"7409","DOI":"10.1016\/j.vaccine.2020.09.079","article-title":"Protection against herpes simplex virus type 2 infection in a neonatal murine model using a trivalent nucleoside-modified mRNA in lipid nanoparticle vaccine","volume":"38","author":"LaTourette","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.trsl.2021.12.006_bib0081","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1128\/iai.29.2.532-538.1980","article-title":"Relationship of antibody to outcome in neonatal herpes simplex virus infections","volume":"29","author":"Yeager","year":"1980","journal-title":"Infect Immun"},{"key":"10.1016\/j.trsl.2021.12.006_bib0082","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1172\/JCI114695","article-title":"Analysis of the role of antibody-dependent cellular cytotoxic antibody activity in murine neonatal herpes simplex virus infection with antibodies to synthetic peptides of glycoprotein D and monoclonal antibodies to glycoprotein B","volume":"86","author":"Kohl","year":"1990","journal-title":"J Clin Invest"},{"key":"10.1016\/j.trsl.2021.12.006_bib0083","doi-asserted-by":"crossref","first-page":"4496","DOI":"10.4049\/jimmunol.1201121","article-title":"Targeting the genital tract mucosa with a lipopeptide\/recombinant adenovirus prime\/boost vaccine induces potent and long-lasting CD8+ T cell immunity against herpes: importance of MyD88","volume":"189","author":"Zhang","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.trsl.2021.12.006_bib0084","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.coi.2004.05.003","article-title":"Immune control of herpes simplex virus during latency","volume":"16","author":"Khanna","year":"2021","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.trsl.2021.12.006_bib0085","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S1074-7613(03)00112-2","article-title":"Herpes simplex virus-specific memory CD8+ T cells are selectively activated and retained in latently infected sensory ganglia","volume":"18","author":"Khanna","year":"2003","journal-title":"Immunity"},{"key":"10.1016\/j.trsl.2021.12.006_bib0086","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1084\/jem.20061792","article-title":"Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation","volume":"204","author":"Zhu","year":"2021","journal-title":"J Exp Med"},{"key":"10.1016\/j.trsl.2021.12.006_bib0087","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.4049\/jimmunol.165.2.1146","article-title":"Long term persistence of herpes simplex virus-specific CD8+ CTL in persons with frequently recurring genital herpes","volume":"165","author":"Posavad","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/j.trsl.2021.12.006_bib0088","doi-asserted-by":"crossref","first-page":"10289","DOI":"10.1073\/pnas.94.19.10289","article-title":"Severe genital herpes infections in HIV-infected individuals with impaired herpes simplex virus-specific CD8+ cytotoxic T lymphocyte responses","volume":"94","author":"Posavad","year":"1997","journal-title":"Proc Nat Acad Sci USA"}],"container-title":["Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524421003030?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524421003030?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T12:44:30Z","timestamp":1761828270000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1931524421003030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":88,"alternative-id":["S1931524421003030"],"URL":"https:\/\/doi.org\/10.1016\/j.trsl.2021.12.006","relation":{},"ISSN":["1931-5244"],"issn-type":[{"value":"1931-5244","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An mRNA vaccine to prevent genital herpes","name":"articletitle","label":"Article Title"},{"value":"Translational Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trsl.2021.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}